Cerdulatinib yields ‘encouraging’ results in CTCL, PTCLFebruary 6, 2019Lymphoma & Plasma Cell DisordersNonmelanoma Skin Cancer
Combo emerges as bridge to transplant in rel/ref PTCLFebruary 5, 2019Lymphoma & Plasma Cell Disorders
GALLIUM: MRD response correlates with outcomes in follicular lymphomaJanuary 31, 2019Lymphoma & Plasma Cell Disorders
IPH4102 on fast track for Sézary syndromeJanuary 30, 2019Lymphoma & Plasma Cell DisordersNonmelanoma Skin Cancer
Umbralisib gains FDA breakthrough designation for MZLJanuary 25, 2019Lymphoma & Plasma Cell Disorders
Novel bispecific CAR shows promise in B-cell malignanciesJanuary 25, 2019Lymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Imaging, radiotherapy clarified in new PMBCL guidelinesJanuary 25, 2019Lymphoma & Plasma Cell Disorders
Are single agents better than chemo for relapsed/refractory PTCL?January 24, 2019Lymphoma & Plasma Cell Disorders
With RRMM and renal impairment, carfilzomib improves survivalJanuary 22, 2019Lymphoma & Plasma Cell Disorders
Zanubrutinib receives breakthrough designation for MCLJanuary 18, 2019Lymphoma & Plasma Cell Disorders
Chidamide may be more effective in PTCL than previously thoughtJanuary 16, 2019Lymphoma & Plasma Cell Disorders
Armored CAR protects T cells, induces remissionsJanuary 4, 2019Immuno-oncologyLymphoma & Plasma Cell DisordersImmunotherapy